Aspartate Beta-Hydroxylase (ASPH) As a Novel Therapeutic Target in Acute Myeloid Leukemia

ConclusionASPH is overexpressed in approximately 40% of patients with AML and serves as a promising therapeutic target. An ASPH nanoparticle vaccine is currently under clinical investigation and has shown promising results in solid tumors. We plan to expand clinical testing of targeting ASPH to AML. The ASPH positivity cutoff established via this work will serve as the eligibility criterion for the planned phase Ib/IIa of anti-ASPH vaccination in AML..DisclosuresLebowitz: Sensei Biotherapeutics: Employment. Malhotra: Sensei Biotherapeutics: Employment. Fuller: Sensei Biotherapeutics: Employment. Shahlaee: Sensei Biotherapeutics: Equity Ownership; Sensei Biotherapeutics: Consultancy. Ghanbari: Sensei Biotherapeutics: Employment; Sensei Biotherapeutics: Equity Ownership. Emadi: NewLink Genetics: Research Funding.
Source: Blood - Category: Hematology Authors: Tags: 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis Source Type: research